Abstract: A tizanidine liquid preparation and use of the tizanidine liquid preparation in the preparation of a medicament for treating muscle spasm, wherein the tizanidine liquid preparation comprises an active ingredient, disodium EDTA and other pharmaceutical excipients, wherein the active ingredient is one or more of tizanidine or a pharmaceutically acceptable salt, solvate and hydrate thereof.
Type:
Grant
Filed:
December 22, 2023
Date of Patent:
July 23, 2024
Assignee:
FIDELITY BIOPHARMA CO.
Inventors:
Gang Chen, Gongzheng Chen, Song Lin, Rashmi Rohit Prasade, Ganesh Dattatray Chavan Patil
Abstract: The invention relates generally to compounds that are Mer-Ax1 inhibitors, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
Type:
Grant
Filed:
May 2, 2019
Date of Patent:
July 16, 2024
Assignee:
Bristol-Myers Squibb Company
Inventors:
Christine M. Tarby, Derek J. Norris, Julian C. Lo, Vijay T. Ahuja, Steven P. Seitz, Ashvinikumar V. Gavai, John S. Tokarski, Mohini Rajasagi, Michael Wichroski, Matthias Broekema
Abstract: A method of reducing the risk of medication-related overdose, death, or other injury associated with inappropriate consumption of alcohol in conjunction with prescription opioid analgesics, comprising: administering a combination medication having an effective amount of one or more opioid medications, and an effective amount of one or more aldehyde dehydrogenase inhibitors, in order to provide the powerful analgesic effects of the opioid in conjunction with a substance that prevents concomitant alcohol consumption, thereby reducing the risk of alcohol mediated opioid overdose or death. A combination medication, including an effective amount of one or more opioid medications, and an effective amount of one or more aldehyde dehydrogenase inhibitors and a pharmaceutically acceptable carrier.
Abstract: Described are compounds of formula (I), based on an isoquinolin-1(2H)-one backbone, that function as Hsp90? selective inhibitors. Also described are pharmaceutical compositions thereof and methods of treating cancer by administering compounds of formula (I).
Type:
Grant
Filed:
May 30, 2019
Date of Patent:
July 9, 2024
Assignees:
University of Notre Dame du Lac, University of Kansas
Abstract: To reveal which curcumin preparation, among various existing curcumin preparations, is effective for various symptoms of a common cold. Provided is an agent for relieving common cold symptom which contains, as an active ingredient, a curcumin-containing composition that contains fine particles of curcumin or turmeric pigment, or a mixture containing curcumin or turmeric pigment containing an amorphous thereof and a cellulose derivative.
Abstract: A method of stimulating ventilatory and/or respiratory drive in a subject in need thereof includes administering to the subject a therapeutically effective amount of a composition comprising an glutathione alkyl ester, adduct thereof, or pharmaceutically acceptable salt, tautomer, or solvate thereof.
Type:
Grant
Filed:
March 16, 2022
Date of Patent:
June 18, 2024
Assignee:
CASE WESTERN RESERVE UNIVERSITY
Inventors:
Stephen J. Lewis, Michael W. Jenkins, James M. Seckler
Abstract: The disclosure relates to norpsilocin compounds, compositions containing those crystalline compounds, and methods of treatment using them. The norpsilocin compounds include crystalline 4-hydroxy-N-methyltryptamine (“crystalline 4-HO-NMT” or “crystalline norpsilocin freebase”), crystalline 4-hydroxy-N-methyltryptammonium fumarate (“crystalline norpsilocin fumarate”), and 4-hydroxy-N-methyltryptammonium fumarate (“norpsilocin fumarate”) and their compositions and uses.
Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and various spondyloarthritic conditions, including types of axial spondyloarthritis (axSpA)), kits, methods of synthesis, and products-by-process. In various aspects, provided are methods for treating active non-radiographic axSpA (nr-axSpA) and methods for treating active ankylosing spondylitis (AS).
Type:
Grant
Filed:
August 21, 2023
Date of Patent:
May 28, 2024
Assignee:
AbbVie Inc.
Inventors:
Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Aileen L. Pangan, In-Ho Song, Ben Klünder, Jeffrey W. Voss, Robert J. Padley, Heidi S. Camp
Abstract: A 2-amino-4-(4-bromophenyl)-6-ethoxypyridine-3,5-dicarbonitrile as an antibacterial compound, its synthesis, and its use as an antibacterial agent.
Type:
Grant
Filed:
November 9, 2023
Date of Patent:
May 21, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer
Abstract: The present invention generally relates to methods and compositions for treating pulmonary infections and inflammation with a composition comprising selenocyanate, hyposelenocyanite or a selenocyanate conjugate.
Abstract: The present invention provides methods for inhibiting respiratory complex III in a cell. The present invention also provides methods for treating cancer in a subject.
Type:
Grant
Filed:
June 4, 2021
Date of Patent:
May 21, 2024
Assignee:
The Regents of the University of California
Abstract: The present disclosure provides, inter alia, methods of treating a solid-tumor by administering an effective amount of a Chemokine Receptor 2 (CCR2) antagonist. Also provided herein are methods of reducing the number of macrophages in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist. In an additional aspect, the current disclosure further provides methods of increasing the number CD8+ T cells in a solid tumor microenvironment, said method comprising administering effective amount of a Chemokine Receptor 2 (CCR2) antagonist.
Type:
Grant
Filed:
December 21, 2020
Date of Patent:
May 21, 2024
Assignee:
CHEMOCENTRYX, INC.
Inventors:
James J. Campbell, Rajinder Singh, Samuel Hwang, Xuesong Wu
Abstract: The invention relates to nutraceutical compositions comprising dopamine transporter inhibitors and to their use as dietary supplements and food additives.
Type:
Grant
Filed:
March 16, 2022
Date of Patent:
May 21, 2024
Assignee:
SPECNOVA LLC
Inventors:
Sebastian Balcombe, William Hamilton, Jonathan Heal, Joseph Sheridan
Abstract: The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting flaviviruses, filoviruses and/or coronaviruses.
Type:
Grant
Filed:
January 6, 2022
Date of Patent:
May 14, 2024
Assignee:
UNIVERSITY OF MARYLAND, BALTIMORE COUNTY
Abstract: The disclosure relates to (2-{4-[(2,2-dimethylpropanoyl)oxy]-1H-indol-3-yl}ethyl)(methyl)azanium chloride (4-pivaloyloxy-N-methyltryptammonium chloride), crystalline 4-pivaloyloxy-N-methyltryptammonium chloride, and specific crystalline forms thereof, including crystalline form 1 of 4-pivaloyloxy-N-methyltryptammonium chloride, to compositions containing the same, and to methods of treatment using them.
Abstract: Disclosed are alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, as Toll-like receptor-7 and -8 agonists for enhancing immune responses. Also provided are methods of making pharmaceutical compositions containing these compounds. The present disclosure also describes methods of use for the alkyl chain modified 1H-imidazoquinoline compounds, derivatives and analogs thereof, and pharmaceutical compositions containing these compounds for the treatment of disease in a subject.
Type:
Grant
Filed:
August 16, 2021
Date of Patent:
May 14, 2024
Assignee:
Dynavax Technologies Corporation
Inventors:
Stewart D. Chipman, Radwan Kiwan, Melissa A. Kachura, Robert Coffman
Abstract: Methods of using glucokinase (GK) activators are generally disclosed herein, particularly in combination with insulin or insulin analogs. In certain aspects, the disclosure provides methods of treating type 1 diabetes that include administering a GK activator in combination with insulin or insulin analogs. Uses of GK activators as a medicament are also disclosed herein, as well as the manufacture of a medicament for such uses.
Type:
Grant
Filed:
February 18, 2021
Date of Patent:
May 7, 2024
Assignee:
VTV THERAPEUTICS LLC
Inventors:
Jennifer L. R. Freeman, Maria Carmen Valcarce Lopez